急性缺血性卒中溶栓门-针时间与1年死亡率和再入院的关系
该回顾性队列研究纳入2006年1月1日至2016年12月31日在Get With The Guidelines-Stroke参与医院接受静脉tPA治疗且距最后正常时间4.5小时内的≥65岁Medicare受益人,随访1年至2017年12月31日。共61 426例,中位年龄80岁,43.5%为男性,中位门-针时间65分钟。门-针时间>45分钟者较≤45分钟者1年全因死亡率更高(35.0% vs 30.8%,校正HR 1.13)、再入院更高(40.8% vs 38.4%,校正HR 1.08);门-针时间>60分钟者较≤60分钟者死亡率更高(35.8% vs 32.1%,校正HR 1.11)。结论认为较短门-针时间与较低1年死亡和再入院相关,支持缩短溶栓时间。
要点
- 门-针时间>45分钟者较≤45分钟者1年全因死亡率更高:35.0% vs 30.8%,校正HR 1.13(95%CI 1.09-1.18)。
- 门-针时间>45分钟者较≤45分钟者1年全因再入院更高:40.8% vs 38.4%,校正HR 1.08(95%CI 1.05-1.12)。
- 门-针时间>60分钟者较≤60分钟者1年全因死亡率更高:35.8% vs 32.1%,校正HR 1.11(95%CI 1.07-1.14)。
- 到达医院90分钟内,门-针时间每增加15分钟与1年全因死亡率升高相关(校正HR 1.04,95%CI 1.02-1.05);90分钟后无显著关联(校正HR 1.01,95%CI 0.99-1.03)。
- 研究结论支持缩短溶栓治疗时间。
适用人群与场景
- ≥65岁Medicare受益人,急性缺血性卒中,在Get With The Guidelines-Stroke参与医院于距最后正常时间4.5小时内接受静脉tPA治疗,2006年1月1日至2016年12月31日。
研究设计与关键结果
- 回顾性队列研究,共61 426例接受tPA治疗且距最后正常时间4.5小时内的患者,中位年龄80岁,43.5%为男性,中位门-针时间65分钟(四分位距49-88分钟)。
- 门-针时间>45分钟者(48 666例,79.2%)较≤45分钟者1年全因死亡率更高(35.0% vs 30.8%,校正HR 1.13,95%CI 1.09-1.18)、全因再入院更高(40.8% vs 38.4%,校正HR 1.08,95%CI 1.05-1.12)、全因死亡或再入院复合终点更高(56.0% vs 52.1%,校正HR 1.09,95%CI 1.06-1.12)。
- 门-针时间>60分钟者(34 367例,55.9%)较≤60分钟者1年全因死亡率更高(35.8% vs 32.1%,校正HR 1.11,95%CI 1.07-1.14)、全因再入院更高(41.3% vs 39.1%,校正HR 1.07,95%CI 1.04-1.10)、全因死亡或再入院复合终点更高(56.8% vs 53.1%,校正HR 1.08,95%CI 1.05-1.10)。
- 到达医院90分钟内,门-针时间每增加15分钟与1年全因死亡率升高相关(校正HR 1.04,95%CI 1.02-1.05);90分钟后无显著关联(校正HR 1.01,95%CI 0.99-1.03)。
- 门-针时间每增加15分钟与1年全因再入院升高相关(校正HR 1.02,95%CI 1.01-1.03),与全因死亡或再入院复合终点升高相关(校正HR 1.02,95%CI 1.01-1.03)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现支持缩短溶栓治疗时间的努力。
- 对于≥65岁急性缺血性卒中患者,在距最后正常时间4.5小时内接受静脉tPA时,较短门-针时间与较低1年全因死亡和再入院相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Earlier administration of intravenous tissue plasminogen activator (tPA) in acute ischemic stroke is associated with reduced mortality by the time of hospital discharge and better functional outcomes at 3 months. However, it remains unclear whether shorter door-to-needle times translate into better long-term outcomes.
OBJECTIVE: To examine whether shorter door-to-needle times with intravenous tPA for acute ischemic stroke are associated with improved long-term outcomes.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included Medicare beneficiaries aged 65 years or older who were treated for acute ischemic stroke with intravenous tPA within 4.5 hours from the time they were last known to be well at Get With The Guidelines-Stroke participating hospitals between January 1, 2006, and December 31, 2016, with 1-year follow-up through December 31, 2017.
EXPOSURES: Door-to-needle times for intravenous tPA.
MAIN OUTCOMES AND MEASURES: The primary outcomes were 1-year all-cause mortality, all-cause readmission, and the composite of all-cause mortality or readmission.
RESULTS: Among the 61 426 patients treated with tPA within 4.5 hours, the median age was 80 years and 43.5% were male. The median door-to-needle time was 65 minutes (interquartile range, 49-88 minutes). The 48 666 patients (79.2%) who were treated with tPA and had door-to-needle times of longer than 45 minutes, compared with those treated within 45 minutes, had significantly higher all-cause mortality (35.0% vs 30.8%, respectively; adjusted HR, 1.13 [95% CI, 1.09-1.18]), higher all-cause readmission (40.8% vs 38.4%; adjusted HR, 1.08 [95% CI, 1.05-1.12]), and higher all-cause mortality or readmission (56.0% vs 52.1%; adjusted HR, 1.09 [95% CI, 1.06-1.12]). The 34 367 patients (55.9%) who were treated with tPA and had door-to-needle times of longer than 60 minutes, compared with those treated within 60 minutes, had significantly higher all-cause mortality (35.8% vs 32.1%, respectively; adjusted hazard ratio [HR], 1.11 [95% CI, 1.07-1.14]), higher all-cause readmission (41.3% vs 39.1%; adjusted HR, 1.07 [95% CI, 1.04-1.10]), and higher all-cause mortality or readmission (56.8% vs 53.1%; adjusted HR, 1.08 [95% CI, 1.05-1.10]). Every 15-minute increase in door-to-needle times was significantly associated with higher all-cause mortality (adjusted HR, 1.04 [95% CI, 1.02-1.05]) within 90 minutes after hospital arrival, but not after 90 minutes (adjusted HR, 1.01 [95% CI, 0.99-1.03]), higher all-cause readmission (adjusted HR, 1.02; 95% CI, 1.01-1.03), and higher all-cause mortality or readmission (adjusted HR, 1.02 [95% CI, 1.01-1.03]).
CONCLUSIONS AND RELEVANCE: Among patients aged 65 years or older with acute ischemic stroke who were treated with tissue plasminogen activator, shorter door-to-needle times were associated with lower all-cause mortality and lower all-cause readmission at 1 year. These findings support efforts to shorten time to thrombolytic therapy.
参考来源
- Man S, Xian Y, Holmes DN, et al. Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke. JAMA. 2020. PMID: 32484532. doi:10.1001/jama.2020.5697
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。